Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
AIDS in the Elderly:New York City Vital Statistics
J Emerg Med 14:19-23, Gaeta,T.J.,et al, 1996
Falls & Fractures in Patients with Alzheimer-Type Dementias
JAMA 257:1492-1495, Buchner,D.M.,et al, 1987
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia
JAMA 314:1242-1254, Cummings, J.L.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Should Patients with Dementia who Wander be Electronically Tagged? Yes
BMJ 346:f3603, McShane, R., 2013
Memantine for Dementia in Adults Older than 40 years with Downs Syndrome (MEADOWS): a Randomised,double-blind,placebo-controlled Trial
Lancet 379:528-536, Hanney,M.,et al, 2012
Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
Antidepressant Treatment in Alzheimers Disease
Lancet 378:375-378, Brodaty, H., 2011
Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:1316-1324, Iverson,D.J., et al, 2010
Predictors of Driving Safety in Early Alzheimer Disease
Neurol 72:521-527, Dawson,J.D.,et al, 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
DNA �-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
JAMA 302:1796-1802, Lambracht-Washington,D.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
A longitudinal Study of Drivers With Alzheimer Disease
Neurol 70:1171-1178, Ott, B.R.,et al, 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Subacute Meningoencephalitis in a Subset of Patients with AD After AB42 Immunization
Neurol 61:46-54,7, Orgogozo,J.M.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000